Basic Information
IVACTA Biotechnology was founded on June 25, 2025, as a spin-off of the in vivo CAR-T platform from Beijing Gracell Biotechnologies Co., Ltd. (hereinafter referred to as "Gracell Biotech"). IVACTA Biotechnology’s in vivo CAR-T therapy, developed based on a targeted LNP delivery system, focuses on bringing revolutionary treatments for hematological tumors and autoimmune diseases. It enables direct expression of CAR within patients’ T cells, eliminating the need for cell separation, expansion, and lymphodepletion pretreatment processes required in traditional autologous CAR-T therapies. This addresses the three core pain points of autologous CAR-T therapies: high cost, long cycle, and significant toxicity. It is expected to significantly shorten the treatment process, achieve the evolution of cell therapy into off-the-shelf drugs, and greatly improve patient accessibility.